85 results about "Immunomodulatory protein" patented technology

A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumor therapy; use in the in-vitro expansion of (e.g. virus-specific) cytotoxic T cells; and therapeutic or prophylactic use in corrective gene therapy.

The invention provides a preparing method of reconstructing immunoregulatory protein of a ganoderma lucidum. The method includes the following steps: construction of engineering bacteria, wherein, LZ-8 protein gene is designed and coded, and is connected with a leading peptide coding sequence of saccharomyces cervisiae alpha-factor into fusion gene, which is transferred to a Pichia Pastoris expression system GS115 for reconstructing expression, high expressed rLZ-8 protein bacterial strain is acquired; the fermentation under the scale of 100L fermentation cylinder, wherein, improved seed culture medium and fermentation medium are used, additions of glycerol and methanol are regulated, 0.5M(NH4)2SO4 is added at the late stage of the fermentation; the purification on a column via centrifugal separation, wherein, salt is hyperfiltrated, powder is prepared after being frozen and dried. The method has large scale of fermentation, optimized technological condition and high production rate.

The invention discloses a recombinant Ganoderma Lucidum immunomodulatory protein (rLZ-8) which has anti-tumor effect and is expressed by Pichia pastoris, and a pharmaceutical preparation thereof. The rLZ-8 has the effect of directly killing or damaging NB4 or K562 or HL-60 or S180 or H22 cells and not affecting normal cells; and the rLZ-8 can quickly and efficiently induce a plurality of tumor cells to apoptosize in vitro, can also effectively kill the tumor cells in a body of a mouse tumor model, has no obvious toxic side effect, and can keep or raise the level of leucocytes. In addition, the invention also provides an anti-tumor pharmaceutical preparation type taking the rLZ-8 as a core composition.

The invention relates to the application of recombinant Ganoderma lucidum immunoregulatory protein rLZ-8 in the preparation of medicine for treating leukopenia caused by chemotherapeutic drugs. The invention establishes a leukopenia disease model in rats caused by cyclophosphamide, and uses the recombinant Ganoderma lucidum immunoregulatory protein to conduct treatment experiments. The experimental results prove that the recombinant Ganoderma lucidum immunomodulatory protein has a very significant effect on increasing white blood cells.

A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.

The invention provides a novel immunomodulatory protein FIP-ppl derived from a fungus by applying a genetic engineering means for the first time. According to the invention, a gene which codes the protein is provided and synthesized. The protein FIP-ppl has immunomodulatory and anti-tumor effect. Experiments verify that the protein has a catalytic splitting effect on splenic lymphocyte and can add synthesis of interleukin 2; the protein has remarkable suppress proliferation and apoptosis-inducing effects of the protein on hepatoma carcinoma cell HepG2 and gastric carcinoma cell MCG823 are further verified. The protein FIP-ppl provided by the invention is lowly homological with almost found immunomodulatory proteins of fungi and is a novel immunomodulatory and anti-tumor biological preparation.

The present invention provides novel virus vaccines with augmented, e.g., enhanced and / or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject.

Methods of inhibiting annexin I induced apoptosis by contacting a cell population containing a TRPM7 / ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase.

The invention relates to recombinant strain capable of expressing fungal immunomodulatory protein from Flammulina velutipes (FIP-fve), a construction method, a protein expression and purification method, and protein application. Existing FIP-fve engineered strains have the disadvantages of low expression rate, expression product of insoluble inclusion body, uncertain structure and broken strain, complex purification process, and non-suitability for large-scale production. The invention adopts FIP-fve gene and Transetta (DE3) as host bacteria to construct recombinant strain; induces expression with isopropyl-beta-d-thiogalactoside (IPTG); treats by combining a lysozyme method and ultrasonic method; and desalts by adopting Ni-His.Band column chromatography and Sephadex G25 gel column chromatography, thereby finishing construction of recombinant strain, expression and purification. The invention is used for preparing drug for preventing or treating allergy. The purification process is simple and rapid, and suitable for large-scale fermentation production.

The invention relates to an improved nucleic acid molecule encoding fungal immunomodulatory protein (FIP) that is better expressed in fungi, to vectors comprising the nucleic acid molecule, to hosts transformed with said vectors, to processes of expressing the protein of the invention in said transformed hosts, to the protein of the invention produced by said processes, to uses of said hosts comprising the protein of the invention and to a process of purifying FIP. The protein of the invention has wide immunomodulatory activity. Thus, the present invention further relates to uses of the protein of the invention in cosmetic or pharmaceutical compositions and to food or feed additives comprising the protein of the invention. Finally, the invention relates to the method of modulating immunological activities by orally administering FIP or proteins fused with FIP to a subject.

This invention relates to a method for stimulation or an activation of immunological function directed to activate natural killer cells and macrophages or increase production of serum antibody in a patient in need of such stimulation or activation, comprising administering an isolated and / or purified polypeptide of a fungal immunomodulatory protein. This invention also relates to a method for suppressing proliferation of a cancer cell and a method for suppressing a tumor cell mobility, comprising providing to the tumor cell a purified polypeptide of a fungal immunomodulatory protein.

The invention, belonging to the filed of genetic engineering technology, relates to a recombinant fungal immunomodulatory protein (FIP) gene in Ganoderma lucidum, a protein coded whereby and an application thereof. The nucleotide sequence of the recombinant FIP gene in Ganoderma lucidum is shown in SEQ ID No.1, and the protein coded by the recombinant FIP gene is shown in SEQ ID No.2. According to the invention, the FIP gene in Ganoderma lucidum is recombined, an object protein is obtained by expressing the recombinant gene in escherichia coli, and the immunomodulating activity of the recombinant gene is proved to be good. The invention provides a new idea and approach for producing FIP in large scale and the application of using FIP as medicine or other health products.

Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.

Disclosed herein is a recombinant viral construct and its uses thereof. The recombinant viral construct is capable of simultaneously expressing three exogenous proteins, including a classical swine fever virus (CSFV) antigen, a porcine circovirus type 2 (PCV2) antigen, and an immunomodulatory protein. The recombinant viral construct is hence useful as a bio-tool for simultaneously producing multiple antigens of a bi-subunit vaccine.

The invention provides a method for promoting wound healing or tissue injury treatment in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more fungal immunomodulatory protein (preferably, Ganoderma immunomodulatory protein).

Disclosed herein is a recombinant viral construct and its uses thereof. The recombinant viral construct is capable of simultaneously expressing three exogenous proteins, including a classical swine fever virus (CSFV) antigen, a porcine circovirus type 2 (PCV2) antigen, and an immunomodulatory protein. The recombinant viral construct is hence useful as a bio-tool for simultaneously producing multiple antigens of a bi-subunit vaccine.

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

The invention discloses a preparation method and application of a recombinant flammulina velutipes immunomodulatory protein that is expressed by Pasteur pichia pastoris, and the preparation method comprises following steps: (1) an encoding FIP-fve gene is cloned; (2) a recombinant Pasteur pichia pastoris expression carrier is constructed; (3) a recombinant Pasteur pichia pastoris transformant is obtained; and (4) the recombinant FIP-fve gene is induction expressed and purified. The preparation method clones an encoding flammulina velutipes immunomodulatory protein, constructs the Pasteur pichia pastoris expression carrier, and consequently obtains the recombinant flammulina velutipes immunomodulatory protein with high yield and high purity. The yield of the recombinant protein that is obtained by the 5-liter fermentation technique reaches 300mg / L to 350mg / L, the purity reaches over 90 percent, and the purified recombinant flammulina velutipes immunomodulatory protein is detected to have the same biologic features and physiological immune activity with natural flammulina velutipes immunomodulatory protein, has procoagulant activity and the promoting functions of mouse lymphocyte proliferation as well as interleukin and interferon secretion, and can induce tumor cell apoptosis.

The invention discloses a method for preparing intragenus recombinant fungal immunomodulatory proteins and application of the intragenus recombinant fungal immunomodulatory proteins. The intragenus recombinant fungal immunomodulatory proteins have a nucleotide sequence shown in SEQ ID NO. 1 in a sequence table. According to the application, genes of the intragenus recombinant fungal immunomodulatory proteins are expressed in Escherichia coli so as to obtain high-expression target proteins, and the condition that the target proteins have good anti-tumor activity to breast and lung cancers is proved, so that novel application directions and exploration ways are provided for the large-scale production of the recombinant fungal immunomodulatory proteins and the application of the recombinant fungal immunomodulatory proteins in development of novel anti-tumor drugs.

Disclosed are compositions, including LcrV antigenic polypeptides, vaccines and antibodies, as well as associated methods for treating and / or preventing Yersinia infection in a host. The invention further provides immunomodulatory LcrV proteins and polypeptides comprising TLR2 and IFN-gammaR-IFN-gamma-binding sequences that stimulate host anti-inflammatory responses and repress pro-inflammatory responses.

The invention discloses a gene of a recombinant fungal immunomodulatory protein (FIP) between ganodermas, a protein coded thereby, and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence is shown as SEQ ID NO.1, and the nucleotide sequence of the protein is shown as SEQ ID NO.2. Recombination of the gene of the fungal immunomodulatory protein is carried out, the recombinant gene is expressed in Escherichia coli, and a target protein is obtained; moreover, the target protein still has good immunomodulatory activity, and a new thought and exploitation way is provided for large-scale production of the FIP and use thereof as medicines or other health products.

This invention relates to a method for stimulation or an activation of immunological function directed to activate natural killer cells and macrophages or increase production of serum antibody in a patient in need of such stimulation or activation, comprising administering an isolated and / or purified polypeptide of a fungal immunomodulatory protein. This invention also relates to a method for suppressing proliferation of a cancer cell and a method for suppressing a tumor cell mobility, comprising providing to the tumor cell a purified polypeptide of a fungal immunomodulatory protein.

The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and / or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and / or diagnostic purposes.

Herein described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into coat proteins or encapsidation intermediate populations. Each population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different coat proteins or encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different coat proteins such that the reassembled VLP displays more than one peptide or other molecule. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.